Protection against Rectal Transmission of an Emtricitabine-Resistant Simian/Human Immunodeficiency Virus SHIV162p3M184V Mutant by Intermittent Prophylaxis with Truvada

被引：32

作者：

Cong, Mian-er ^{[1
]}

Youngpairoj, Ae S. ^{[1
]}

Zheng, Qi ^{[1
]}

Aung, Wutyi ^{[1
]}

Mitchell, James ^{[1
]}

Sweeney, Elizabeth ^{[1
]}

Hanson, Debra L. ^{[1
]}

Hendry, R. Michael ^{[1
]}

Dobard, Charles ^{[1
]}

Heneine, Walid ^{[1
]}

Garcia-Lerma, J. Gerardo ^{[1
]}

机构：

[1] CDC, Branch Lab, Div HIV AIDS Prevent,Ctr Dis Control & Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA 30329 USA

来源：

JOURNAL OF VIROLOGY | 2011年 / 85卷 / 15期

关键词：

ANTIRETROVIRAL DRUG-RESISTANCE; REVERSE-TRANSCRIPTASE; SEXUAL TRANSMISSION; RHESUS MACAQUES; MUTATIONS; FITNESS; TYPE-1; K65R; CHEMOPROPHYLAXIS; EPIDEMIOLOGY;

D O I：

10.1128/JVI.00843-11

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Daily preexposure prophylaxis (PrEP) with Truvada (emtricitabine [FTC] and tenofovir disoproxil fumarate [TDF]) is a novel HIV prevention strategy recently found to reduce HIV incidence among men who have sex with men. We used a macaque model of HIV transmission to investigate if Truvada maintains prophylactic efficacy against an FTC-resistant isolate containing the M184V mutation. Five macaques received a dose of Truvada 3 days before exposing them rectally to the simian/human immunodeficiency virus mutant SHIV162p3(M184V), followed by a second dose 2 h after exposure. Five untreated animals were used as controls. Virus exposures were done weekly for up to 14 weeks. Despite the high (>100-fold) level of FTC resistance conferred by M184V, all five treated animals were protected from infection, while the five untreated macaques were infected (P = 0.0008). Our results show that Truvada maintains high prophylactic efficacy against an FTC-resistant isolate. Increased susceptibility to tenofovir due to M184V and other factors, including residual antiviral activity by FTC and/or reduced virus fitness due to M184V, may all have contributed to the observed protection.

引用

页码：7933 / 7936

页数：4

共 29 条

[1] Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection [J].